Advisory Research Inc. Raises Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Posted by Defense World Staff on Mar 15th, 2023

Advisory Research Inc. increased its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) by 56.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 96,803 shares of the company’s stock after buying an additional 34,999 shares during the quarter. Advisory Research Inc. owned about 0.06% of Recursion Pharmaceuticals worth $1,030,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Albion Financial Group UT raised its position in shares of Recursion Pharmaceuticals by 3,385.0% in the 3rd quarter. Albion Financial Group UT now owns 4,182 shares of the company’s stock worth $44,000 after buying an additional 4,062 shares during the period. Baldwin Brothers LLC MA raised its position in shares of Recursion Pharmaceuticals by 100.0% in the 3rd quarter. Baldwin Brothers LLC MA now owns 5,502 shares of the company’s stock worth $59,000 after buying an additional 2,751 shares during the period. Rockefeller Capital Management L.P. raised its position in shares of Recursion Pharmaceuticals by 23.2% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 7,319 shares of the company’s stock worth $77,000 after buying an additional 1,378 shares during the period. Martingale Asset Management L P purchased a new position in shares of Recursion Pharmaceuticals in the 2nd quarter worth $91,000. Finally, SG Americas Securities LLC purchased a new position in shares of Recursion Pharmaceuticals in the 2nd quarter worth $96,000. 63.62% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Trading Down 0.5 %

Shares of NASDAQ RXRX opened at $7.63 on Wednesday. Recursion Pharmaceuticals, Inc. has a 12-month low of $4.92 and a 12-month high of $14.18. The company has a market cap of $1.46 billion, a P/E ratio of -5.57 and a beta of -0.33. The stock has a fifty day moving average price of $8.21 and a 200 day moving average price of $9.46.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) last announced its quarterly earnings results on Monday, February 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.16). Recursion Pharmaceuticals had a negative net margin of 601.05% and a negative return on equity of 53.07%. The company had revenue of $13.68 million during the quarter, compared to analyst estimates of $66.68 million. On average, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.33 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, SVB Leerink lowered their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Monday, January 23rd.

Insider Activity

In other news, insider Shafique Virani sold 10,000 shares of the firm’s stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $8.85, for a total transaction of $88,500.00. Following the completion of the sale, the insider now directly owns 78,160 shares in the company, valued at $691,716. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Shafique Virani sold 10,000 shares of the firm’s stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $8.85, for a total transaction of $88,500.00. Following the completion of the sale, the insider now directly owns 78,160 shares in the company, valued at $691,716. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Mubadala Investment Co Pjsc bought 6,300 shares of the stock in a transaction dated Tuesday, February 14th. The shares were acquired at an average price of $7.95 per share, with a total value of $50,085.00. Following the completion of the purchase, the insider now directly owns 12,404,518 shares of the company’s stock, valued at $98,615,918.10. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 581,017 shares of company stock worth $4,440,853 and sold 212,686 shares worth $1,719,723. Insiders own 22.25% of the company’s stock.

About Recursion Pharmaceuticals

(Get Rating)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.